DOCSLIB.ORG

MEET SANOFI Management Forward Looking Statements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MEET SANOFI Management Forward Looking Statements MEET SANOFI Management Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. 2 2015-2020 ROADMAP Olivier Brandicourt Chief Executive Officer MEET SANOFI Management Agenda Our vision for Sanofi Sanofi’s path to success Delivering performance 4 Many Elements Point towards a Favorable Outlook for the Healthcare Industry despite Multiple Challenges Opportunities Challenges Growing and aging population Affordability is a key concern globally Unmet medical needs remain high Price pressure from payers in developed markets Improved R&D productivity across the industry Biosimilar threat and risk of interchangeability Exciting time scientifically Slowdown in economic growth Rising middle class in Emerging in Emerging Markets Markets More focused competitors building Empowered patients leadership positions 5 Sanofi Has Important Strengths to Build On in this Changing Environment Launching a strong set Leading of products Making credible positions in across multiple TAs entry in new TAs Diabetes, Vaccines, e.g. Multiple Rare Diseases, Sclerosis Emerging Markets Record of Strong skills building leading for managing brands: Successful in mature Lantus®, Fluzone®, sourcing external businesses Cerezyme® innovation: Regeneron, Alnylam, Voyager TA: Therapeutic Areas 6 Sanofi Also Has Challenges to Address in Order to Succeed 1 Broad portfolio 2 Lantus® loss of exclusivity 3 Pressure on margins 4 Limited breadth of pipeline 5 Complexity 7 A New Strategic Direction for Sanofi Is Needed to Change our Growth Trajectory Sanofi is a global healthcare company focused on disease prevention and treatment ● DIVERSIFIED in Pharmaceuticals, Vaccines and Consumer Healthcare Our Vision for Sanofi ● FOCUSED on 5 GBUs(1) ● INNOVATIVE to sustain long term growth ● SIMPLIFIED as an organization (1) Diabetes/Cardiovascular, General Medicines and Emerging Markets, Specialty Care, Vaccines, Animal Health 8 Agenda Our vision for Sanofi Sanofi’s path to success Delivering performance 9 We Have Four Strategic Priorities 1 2 3 Deliver Sustain Reshape outstanding innovation the portfolio launches in R&D 4 Simplify the organization 10 1 Reshape the Portfolio Sustain Build competitive Explore strategic A B C leadership positions options ● Diabetes/CV ● Multiple Sclerosis(1) ● Animal Health ● Vaccines ● Oncology(1) ● Generics(2) in Europe ● Rare Diseases(1) ● Immunology(1) ● Emerging Markets(2) ● Consumer Healthcare(2) (1) Will be part of Specialty Care Global Business Unit (2) Will be part of General Medicines and Emerging Markets Global Business Unit 11 A Committed to Diabetes and Cardiovascular Diseases 1 Develop the insulin franchise Strengthen the pipeline through external opportunities 2 and ambitious research 3 Lead the market shift to managing diabetes outcomes Google Life Sciences 4 Transform the management of hypercholesterolemia Ambition to grow Diabetes franchise beginning in 2019(1) Praluent® multi-blockbuster potential (1) Diabetes sales are expected to decline at an average annualized rate of -4% to -8% at CER over 2015-2018 Icons designed by Freepik 12 Strengthening our R&D Portfolio in Diabetes A with Two In-Licensing Agreements (2) Immunology Sotagliflozin - Phase II in T2 Diabetes Efpeglenatide – Phase II Phase III in T1 Diabetes ● Long acting GLP-1(3) (1) ● Dual SGLT1 and SGLT2 inhibitor ● Diabetes/Obesity ● Limiting meal time glucose absorption and ● Weekly/monthly administration increasing renal glucose excretion LAPS ● Oral administration Insulin 115 (HM12470) – Phase I ● Adjunct therapy ● Long acting insulin to insulin ● Less side-effects (hypoglycemia, obesity) in T1DM ● Weekly administration ● Favorable safety profile LAPS Insulin Combo – Pre-clinical ● Long acting insulin + efpeglenatide combination ● Weekly administration T1DM: Diabetes mellitus type 1 (1) SGLT2 (sodium-glucose cotransporter type 2) is a transporter responsible for most of the glucose reabsorption performed by the kidney SGLT1 (sodium-glucose cotransporter type 1) is a transporter responsible for glucose and galactose absorption in the gastrointestinal tract, and to a lesser extent than SGLT2, glucose reabsorption in the kidney (2) Subject to customary closing conditions 13 (3) LAPS CA-Exendin-4 analog A Growing Faster than Market in Vaccines Projected Sanofi Pasteur Sales 1 Further develop strong vaccine brands High ● Flu vaccines single digit ● Pediatric combinations sales CAGR ● Adult boosters at CER ® ~75% 2 Successfully launch Dengvaxia ~€4.7bn Dengue of €4.0bn sales Flu 3 Expand our manufacturing capacity Pediatric & boosters 4 Deliver novel high-value vaccines e.g. C. diff vaccine 2014 2015e 2020e 14 A Sustaining Leadership in Rare Diseases Undiagnosed(1) Undiagnosed(1) Undiagnosed(1) ●1 Sustain market share through patient-centered approach, product differentiation and market access ●2 Grow market through patient screening and manufacturing expansion ●3 Advance internal and partnered novel pipeline Sales CAGR for Rare Diseases expected at high single digit at CER over 2015-2020 (1) Genzyme internal analysis. Include China and India 15 Retaining #1 Position in Emerging Markets A through Greater Focus Leader in Emerging Markets EM sales ~€10.8bn in 2015e ●1 Increase focus on priority countries/regions (1) ~29% of Group sales ● Prioritize resource allocation A top 3 MNC player in BRIC-M ● Adapt industrial footprint ● Redefine scope to exclude Eastern Europe(1) #3 in China ●2 Win the emerging middle class #1 in Brazil #2 in Russia ●3 Innovate specifically for Emerging Markets #4 in India ●4 Optimize trade and channel management #2 in Mexico MNC: Multinational corporation (1) World excluding U.S., Canada, Western & Eastern Europe (except Russia, Ukraine, Georgia, Belarus and Armenia), Japan, South Korea, Australia, New Zealand and Puerto Rico 16 1 Reshape the Portfolio Sustain Build competitive Explore strategic A B C leadership positions options ● Diabetes/CV ● Multiple Sclerosis(1) ● Animal Health ● Vaccines ● Oncology(1) ● Generics(2) in Europe ● Rare Diseases(1) ● Immunology(1) ● Emerging Markets(2) ● Consumer Healthcare(2) (1) Will be part of Specialty Care Global Business Unit (2) Will be part of General Medicines and Emerging Markets Global Business Unit 17 B Growing our Multiple Sclerosis Franchise Multiple Sclerosis Franchise Reported sales (€m) €923m ●1 Successfully complete global launches of Aubagio® and Lemtrada® Série2 ●2 Expand LCM activities to maximize Série1 ® support to existing products ●3 Reinforce presence in “high efficacy” category ●4 Enter the neuroprotection/ remyelination segment Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2013 2013 2013 2013 2014 2014 2014 2014 2015 2015 2015 Ambition to double the size of the MS franchise from 2015 to 2020 LCM: Life Cycle Management 18 B Rebuilding a Competitive Position in Oncology Oncology Opportunity Largest therapeutic area for pharmaceuticals ●1 Maximize clinical assets, particularly isatuximab (anti-CD38 mAb) and Antibody-Drug Conjugates Strong growth driven by unmet need and ●2 Build a transformative pipeline groundbreaking science ● Immuno-oncology
Load more

Recommended publications
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
    [Show full text]
  • Robert J. Desalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944
    Robert J. DeSalvo Papers Business Combinations in the Cosmetic and Pharmaceutical Industries 1944 - 1990 Collection #107 Abstract Robert J. DeSalvo’s research focused on business combinations (acquisitions, mergers, and joint ventures in the cosmetic and pharmaceutical industries. This topic was the basis for his master’s thesis in pharmacy administration at the University of Pittsburgh and continued as a life-long interest. This collection consists of two series of notebooks that Dr. DeSalvo developed to record relevant business combinations. The first series records acquisitions, proposed acquisitions, mergers, and joint ventures for the period of 1944 –1990 in an alphabetical arrangement. The information on these entries is cumulative so that the history of an organization is collected in one place. The second series of notebooks is arranged in chronological blocks. The information is arranged alphabetically by the name of the acquirer. The name of the acquired (merged), type of combination (acquisition, proposed acquisition, joint venture) and the date is also provided. The information is cross-referenced between the two series so that the researcher can approach the information by the name of the parent company or chronologically. Dr. DeSalvo used this resource for many of his publications as well as his master’s thesis. A copy of these publications and his thesis make up the remainder of the collection. Donor Gift of Barbara DeSalvo, 2000 Biography Robert James DeSalvo was born on July 20, 1933 in Toledo, OH. He died on January 23, 1993 in Cincinnati, OH. DeSalvo graduated from high school in Toledo and attended pharmacy school at the University of Toledo where he received his B.S.
    [Show full text]
  • 2017 Annual Report on Form
    FORM 20-F 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share New York Stock Exchange Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2017 was: Ordinary shares: 1,254,019,904 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report on Form 20-F 2018
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share NASDAQ Global Select Market Ordinary shares, par value €2 per share NASDAQ Global Select Market* Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2018 was: Ordinary shares: 1,245,454,385 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report on Form 20-F 2014
    FORM 20-F 2014 FORM 20-F 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) Ⅺ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ࠚ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or Ⅺ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or Ⅺ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boetie,´ 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boetie,´ 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one New York Stock Exchange ordinary share, par value e2 per share Ordinary shares, par value e2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2014 was: Ordinary shares: 1,319,367,445 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • PPCO Twist System
    Connect. Collaborate. Contribute. NOVEMBER 2016 Sanofi Genzyme: Expanding Beyond Rare Disease Into Specialty Care p. 18 David Meeker, executive VP and head, Sanofi Genzyme Clinical Trials 26 Allergan R&D 30 Biopharma 32 DC Insider 10 How A Chief Medical Officer Why The Company Women In Bio: Looking CEO Corner 12 Changed The Data-sharing Is Focusing On An Through The Glass Ceiling Culture At J&J And Across “Open-Science Platform” Companies To Watch 16 The Industry Global Update 48 Bringing together the best of When it’s YOUR compound, every step matters. www.pfizercentreone.com API DRUG PRODUCT PC1-16-0005-8.25x10.875 in-Mar., 2016 © 2016 Pfizer Inc. All rights reserved. inVentiv Health. Genetically engineered for success in the new pharmaceutical world. inVentiv Health processes and capabilities can accelerate business performance. The fact is, getting a new drug across the fi nish line is hard work every day. But lately, the challenges have increased exponentially. Today, it’s not enough to simply obtain regulatory approval; market success is now as mission-critical as trial success. Smart outsourcing partners begin with the end in mind. That’s why inVentiv purpose-built an organization in which both clinical and commercial work together under one roof as teammates and colleagues, not distant relatives. From early development through product launch, they share knowledge capital, data and insights. Our superior clinical trial design combined with highly effective commercial launch capabilities creates a unique environment in which processes and systems are constantly being challenged and evolved with an eye towards greater effi ciency, higher quality and, of course, getting to market faster.
    [Show full text]
  • Sanofi 1 4.5
    DOCUMENT DE RÉFÉRENCE 2017 SOMMAIRE 4 RESPONSABILITÉ SOCIALE, AVERTISSEMENT AU LECTEUR I ENVIRONNEMENTALE CHIFFRES CLÉS III ET SOCIÉTALE 355 ABRÉVIATIONS VI 4.1. Informations sociales 356 4.2. Informations santé, sécurité, environnement 371 4.3. Informations relatives aux 1 engagements sociétaux en faveur du développement durable 386 4.4. Plan de vigilance 400 PRÉSENTATION DE SANOFI 1 4.5. Note méthodologique sur le reporting des données 403 1.1. Principales informations relatives à 4.6. Rapport de l’organisme tiers la société 2 indépendant 407 1.2. Gouvernement d’entreprise 8 4.7. Tableau des indicateurs des entités juridiques france 410 2 5 ACTIVITÉ DE SANOFI 77 SANOFI ET SES ACTIONNAIRES 413 2.1. Historique et évolution de la société 79 5.1. Sanofi en bourse 414 2.2. Présentation de l’activité de Sanofi 79 5.2. L’information aux actionnaires 417 2.3. Organisation de l’entreprise 128 2.4. Investissements – principaux établissements 129 2.5. Litiges 133 6 2.6. Événements récents 136 PERSONNES RESPONSABLES, 3 ATTESTATION ET TABLES DE CONCORDANCE 421 6.1. Personne responsable RAPPORT DE GESTION, du document de référence 422 ÉTATS FINANCIERS ET 6.2. Attestation du responsable du document de référence INFORMATIONS FINANCIÈRES contenant un rapport financier COMPLÉMENTAIRES 137 annuel 422 3.1. Rapport de gestion relatif à 6.3. Personnes responsables l’exercice 2017 138 du contrôle des comptes 422 3.2. Rapport de la direction de Sanofi 6.4. Rapport des commissaires sur le contrôle interne relatif à aux comptes sur les prévisions l’information financière 203 de bénéfice net des activités par action 423 3.3.
    [Show full text]
  • Sanofi-Aventis
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ................... For the transition period from to Commission File Number: 001-31368 Sanofi-Aventis (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 174, avenue de France, 75013 Paris, France (Address of principal executive offices) Karen Linehan, Senior Vice President Legal Affairs and General Counsel 174, avenue de France, 75013 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Name of each exchange Title of each class: on which registered: American Depositary Shares, each New York Stock Exchange representing one half of one ordinary share, par value €2 per share Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Securities registered pursuant to Section 12(g) of the Act: American Depositary Shares, each representing one quarter of a Participating Share Series A, par value €70.89 per share (removed from listing and registration on the New York Stock Exchange effective July 31, 1995).
    [Show full text]
  • Sanofi Fires Viehbacher After Fall out with Board
    OTC07-11-14p1_OTC15/11/2005 p1&24 05/11/2014 09:07 Page 1 7November 2014 COMPANY NEWS 3 Bayertakes leading spot 3 Sanofi fires Viehbacher in ChinawithDihon deal BoehringersaysnotoOmegabuy 3 GSKhints at Consumer divestments 4 afterfall out with board Merck waves goodbye to 5 Consumer Care business hris Viehbacher,chief executive officer Bayertargets critical mass 6 in Consumer Cof Sanofi, has been firedafter the firm’s board of directors concluded that his “man- Nasacortdrives salesforward 7 at Sanofi agement style was not adequate”. Oriola wantsafairprice 8 In asurprise move,the board of the French for itsRussian operations companyannounced it had “decided unani- BioGaiareports a 9 mously” to remove Viehbacher after six years double-digitsales rise at the helm. Celesioputsfaith in 11 “The group needs to pursue its development new leadership team with amanagement aligning the teams, harness- Pfizer expects Lipitortrialresults 12 ing talent and focusing on execution with aclose in 2015 and confident co-operation with the board,” Sanofistated, adding that its chairman, Serge GENERAL NEWS 13 Weinberg, would takecharge while it search- ed for achief executive. Most Germans have 13 Expanding on the rationale behind the deci- used homoeopathy sion, Weinbergsaid that the board was“strongly Chris Viehbacher has left Sanofi after the board Health Canada approves 16 dissatisfied” with Viehbacher’sability to work Aspirin heart-attack claim criticised his management style with board members to examine the company’s Germans reject OTCguidance 16 strategy “in aconfident manner”. (OTC bulletin,27February 2009, page 1). Australia settooverhaul 17 “The fluidity of the relationship between Acquisitions were central to Viehbacher’s TGAmedicines regulation the chief executive officer and the board was expansion strategy,with the companysnapping MARKETING NEWS 18 inadequate,”herevealed.
    [Show full text]
  • Annual Report on Form 20-F 2018
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value€2 per share NASDAQ Global Select Market Ordinary shares, par value€2 per share NASDAQ Global Select Market* Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2018 was: Ordinary shares: 1,245,454,385 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Sanofi R&D Chief Zerhouni
    Scrip Asks... IO Roundtable Expert View Do experts see orphan drug pricing Five companies talk about their place New products are set to shake the coming under pressure over the next in immuno-oncology (p10) hemophilia market – but convincing five years? (p4) payers will be a challenge (p14) 10 March 2017 No. 3844 Scripscrip.pharmamedtechbi.com Pharma intelligence | informa consultant to Sanofi; it gained steam when he joined Sanofi in his present position. “I structured the strategy for Sanofi in two phases. The first phase was how do we build a pipeline to be delivered in 2015, 2016, 2017 when we had loss of exclusiv- ity on key products, with Lantus being the last major drug after Plavix and others that lost their patents. The goal was how to do it without breaking the bank,” Zerhouni told Scrip in a recent interview. That initial revamp involved overhauling the pipeline and trimming 19 Phase II and Phase III programs from Sanofi’s R&D pipe- line between 2009 and 2012. Some of the programs missed Phase II endpoints. Oth- ers were discontinued because the value Elias Zerhouni proposition wasn’t there from either the patient or payer perspective. “I modified the strategy in a big way, by putting development first: we have to Sanofi R&D Chief Zerhouni: take care of development and underneath all that, start to fix research, not the other way around. Most heads of R&D, are heads How I’m Doing More With Less of R&D; I said, ‘No, I want to be a head of Elias Zerhouni says Sanofi’s ongoing R&D revamp has produced improved D&R,’ rather than R&D at Sanofi,” Zerhouni innovative results with controlled spending, in part by emphasizing cutting- explained.
    [Show full text]
  • FORM 20-F 2015 UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    FORM 20-F 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 001-31368 Sanofi (Exact name of registrant as specified in its charter) N/A (Translation of registrant’s name into English) France (Jurisdiction of incorporation or organization) 54, Rue La Boétie, 75008 Paris, France (Address of principal executive offices) Karen Linehan, Executive Vice President Legal Affairs and General Counsel 54, Rue La Boétie, 75008 Paris, France. Fax: 011 + 33 1 53 77 43 03. Tel: 011 + 33 1 53 77 40 00 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class: Name of each exchange on which registered: American Depositary Shares, each representing one half of one ordinary share, par value €2 per share New York Stock Exchange Ordinary shares, par value €2 per share New York Stock Exchange (for listing purposes only) Contingent Value Rights NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None The number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2015 was: Ordinary shares: 1,305,696,759 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]